Warning: UK E-liquids may Contain Dangerous Synthetic Drugs

Regulations by 2FIRSTS.ai
Feb.08.2024
Warning: UK E-liquids may Contain Dangerous Synthetic Drugs
Warning: Some e-liquids sold in the UK may contain illicit substances, including synthetic cannabinoids known as "spice."

Recently, health experts in Wales, UK issued a warning claiming that e-liquids being sold in the country may contain synthetic marijuana compounds known as "Spice". They argue that these illicit e-liquids have extremely potent medicinal effects and pose a danger to users who opt for counterfeit prescription drug e-cigarette products.

 

Some e-liquids consumed by UK consumers in their daily lives contain cannabis, CBD, or tetrahydrocannabinol (THC). Recently, WEDINOS, the only nationwide drug testing service in the UK, conducted tests and found that certain e-liquids being sold in the market also contain a potent synthetic drug known as synthetic cannabinoid receptor agonists (SCRAs), sometimes referred to as "spice." Based on these test results, the Welsh public health department has stated that some of these products being sold in the UK pose significant risks to consumers.

 

Synthetic cannabinoid receptor agonists (SCRAs) are a group of compounds associated with significant health issues, ranging from respiratory difficulties to psychiatric episodes. The latest data from WEDINOS, an organization, reveals that out of the 196 liquid samples submitted to them in 2023, 75 samples (almost one-third) contained one or more SCRA compounds.

 

These samples were purchased in the form of cannabis, CBD, or THC e-liquids. Among the number of hospitalizations due to illicit drugs, opioids are the most prevalent, followed by cannabis and synthetic cannabinoids such as Spice. Opioids also remain the most likely type of drug to be associated with drug-related deaths.

 

Experts from the agency have expressed concern over a significant increase in the number of counterfeit prescription drug samples they have received, which have been contaminated with potentially hazardous substances. They have also frequently detected the presence of benzodiazepines, a class of drugs commonly purchased as prescription medication, such as diazepam and hydrocodone.

 

These highly concentrated synthetic opioid medications can pose a threat to life, and there is a significant risk of overdosing. Last year, WEDINOS received 90 samples containing nitrous nitrogen drugs, with nearly 50% purchased under the mistaken belief of being an anti-anxiety medication called diazepam.

 

Professor Rick Lines, the Head of Drug Abuse at the Welsh Public Health Department, has highlighted the need to recognize the increased risk of medication overdose associated with high-concentration drugs. "Our concern is that people who purchase e-cigarettes online may not actually be receiving what they believe they are getting," he cautioned.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden Threatens EU Tobacco Tax Deal as Nicotine Pouch Duty Dispute Looms Over November 9 Meeting
Sweden is expected to oppose a European Union proposal to raise minimum tobacco excise duties, Law360 reported on October 26, 2026, citing an EU official. A provisional Council agenda dated October 23 confirms that the tobacco taxation package is scheduled for discussion at the November 9 finance ministers' meeting, where member states will seek a general approach. The proposed reforms would raise minimum taxes on conventional tobacco products and establish EU-wide excise rules for vaping liquids, heated tobacco and nicotine pouches. Sweden supports harmonising tobacco taxation rules but objects to requiring nicotine pouches to bear the same minimum tax burden as certain smoking tobacco products. As EU indirect tax legislation requires unanimous Council approval, Swedish opposition could block the proposal in its current form.
Regulations
Oct.29
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
2Firsts Interview | Cigarette Sales Fall as Smokeless Alternatives Gain in U.S. Convenience Stores, NACS Says
Ahead of the 2026 NACS Show, 2Firsts interviewed Chris Rapanick, NACS managing director of research, on changes reshaping the U.S. convenience-store tobacco and nicotine market. NACS data show cigarette sales declining while smokeless alternatives, including nicotine pouches, continue to grow. The interview also examines higher OTP margins, shifting backbar space, weaker store traffic, regulatory uncertainty and NACS’ outlook for 2027, offering a retailer-side view of one of the world’s largest nicotine markets.
Interview
Oct.03
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU Tobacco Tax Reform Stalls as Malta Withholds Support Despite Backing From 26 States
EU finance ministers failed to reach agreement on tobacco excise reform at the November 9, 2026 Economic and Financial Affairs Council (ECOFIN) meeting in Brussels. The Irish Council presidency's compromise secured support from 26 of the EU's 27 member states, but Malta withheld consent, preventing the Council from reaching a general approach requiring unanimity. The reform would raise minimum taxes on conventional tobacco and bring e-cigarette liquids, heated tobacco and nicotine pouches into a common EU minimum excise framework. Finland and Estonia accepted further concessions during the meeting, while the presidency proposed separating the inclusion of nicotine pouches in the framework from setting their precise minimum tax rates. Another compromise would allow ten qualifying member states until 2036 to meet certain tobacco excise requirements. Ireland intends to continue negotiations in December.
Regulations
Nov.11
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's regional vape retail restrictions are expanding. State Duma Speaker Vyacheslav Volodin said on November 7 that 17 regions had adopted decisions to ban vape sales, while another 39 were preparing or considering similar legislation. On November 12, lawmakers in Leningrad Oblast and the Republic of Karelia adopted bans scheduled to begin on March 1, 2027. A day earlier, St. Petersburg unanimously approved a five-year ban proposal in its first reading. The city has 615 specialist vape shops and more than 2,400 other retail outlets selling vaping products alongside other goods. Under Federal Law No. 186-FZ, enacted in June 2026, Russian regions may prohibit retail sales of electronic nicotine delivery systems and related liquids between March 2027 and March 2032. The legislation also restricts licensed suppliers from delivering covered products to retail premises in regions where bans apply.
Regulations
Nov.13
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10